It is Gilead’s largest acquisition since it acquired Kite Pharma in 2017 for $11.9 billion, according to Endpoints News.
Gilead paid more than twice what Forty Seven’s market cap was before word spread that Gilead had approached Forty Seven with an offer, Endpoints News reported. Other companies were reportedly also trying to buy Forty Seven.
The acquisition includes an antibody developed by Forty Seven to treat blood cancers that has shown promising results and that Gilead said could become a “first-in-class therapy.”
The deal is expected to close in the second quarter of this year.
Read the full news release here.
More articles on pharmacy:
CVS prescription mistakes prompt probe of staffing levels at Oklahoma pharmacy
Senators threaten to subpoena Express Scripts over insulin documents
GoodRx sharing patient data with Google, Facebook
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.